China Isotope & Radiation (HKSE:01763) EBITDA Margin % : 15.22% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. China Isotope & Radiation's EBITDA for the six months ended in Dec. 2023 was HK$648 Mil. China Isotope & Radiation's Revenue for the six months ended in Dec. 2023 was HK$4,260 Mil. Therefore, China Isotope & Radiation's EBITDA margin for the quarter that ended in Dec. 2023 was 15.22%.

China Isotope & Radiation EBITDA Margin % Historical Data

The historical data trend for China Isotope & Radiation's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation EBITDA Margin % Chart

China Isotope & Radiation Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

22.17

18.79

20.14

19.16

18.43

China Isotope & Radiation Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial											17.61	12.58	17.73	13.35	15.22

Competitive Comparison of China Isotope & Radiation's EBITDA Margin %

For the Medical Devices subindustry, China Isotope & Radiation's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Isotope & Radiation's EBITDA Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's EBITDA Margin % falls into.

China Isotope & Radiation EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

China Isotope & Radiation's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1337.615	/	7257.214
	=	18.43 %

China Isotope & Radiation's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	648.278	/	4259.619
	=	15.22 %

China Isotope & Radiation (HKSE:01763) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

China Isotope & Radiation EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Isotope & Radiation (HKSE:01763) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089

Website

https://www.china-isotope.com

China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Li Hongbo	2201 Interest of corporation controlled by you
Lianwen Ltd	2101 Beneficial owner
Invesco Advisers, Inc.	2102 Investment manager
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Invesco Hong Kong Limited	2102 Investment manager
Invesco Corporate Class Inc.	2106 Person having a security interest in shares
M&g Plc	2201 Interest of corporation controlled by you
Shanghai Industrial Holdings Limited	2201 Interest of corporation controlled by you
Shanghai Industrial Investment (holdings) Company Limited	2201 Interest of corporation controlled by you
Serenity Investment Master Fund Limited	2101 Beneficial owner
Serenity Capital Management, Ltd.	2102 Investment manager
Shanghai Pharmaceuticals Holding Co., Ltd.	2201 Interest of corporation controlled by you
S.i. Infrastructure Holdings Limited	2201 Interest of corporation controlled by you

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines